Key points are not available for this paper at this time.
This mini-review will summarize the present state of development of the CD38 antibody daratumumab for the treatment of multiple myeloma.
Plesner et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: